Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 30, 2024Nature CommunicationsOpen Access

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial

View Full Paper
Ask AI
Bookmark
Share

Authors

CPChanghee ParkDaegu Gyeongbuk Institute of Science and TechnologyHLHo Sup LeeKosin University Gospel HospitalKKKa‐Won KangKorea University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Park et al. (2024) studied this question.

synapsesocial.com/papers/68e719e1b6db6435876935bchttps://doi.org/10.1038/s41467-024-47198-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,746 citations
  2. 2A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia2013 · 353 citations
  3. 3Practical issues in CAR T-cell therapy2023 · 15 citations
  4. 4Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma2016 · 379 citations